These promising clinical results paved the way for the CLIMB THAL-111 and CLIMB SCD-121 trials, testing the efficacy of CRISPR–Cas9 gene editing of autologous CD34+ (Exa-cel) to treat TDT and SCD, respectively. The gene discussed is CD34; the disease is Schnyder corneal dystrophy.